EP1095154A2 - Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon) - Google Patents

Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon)

Info

Publication number
EP1095154A2
EP1095154A2 EP99932376A EP99932376A EP1095154A2 EP 1095154 A2 EP1095154 A2 EP 1095154A2 EP 99932376 A EP99932376 A EP 99932376A EP 99932376 A EP99932376 A EP 99932376A EP 1095154 A2 EP1095154 A2 EP 1095154A2
Authority
EP
European Patent Office
Prior art keywords
app
hslon
complex
derivative
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99932376A
Other languages
English (en)
French (fr)
Inventor
Krishnan Nandabalan
Meijia Yang
Vincent Peter Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Publication of EP1095154A2 publication Critical patent/EP1095154A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
EP99932376A 1998-07-10 1999-07-08 Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon) Withdrawn EP1095154A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11334898A 1998-07-10 1998-07-10
US113348 1998-07-10
PCT/US1999/015592 WO2000002911A2 (en) 1998-07-10 1999-07-08 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON)

Publications (1)

Publication Number Publication Date
EP1095154A2 true EP1095154A2 (de) 2001-05-02

Family

ID=22348923

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99932376A Withdrawn EP1095154A2 (de) 1998-07-10 1999-07-08 Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon)

Country Status (5)

Country Link
EP (1) EP1095154A2 (de)
JP (1) JP2002521004A (de)
AU (1) AU4869399A (de)
CA (1) CA2332625A1 (de)
WO (1) WO2000002911A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379620B1 (en) 1998-11-16 2002-04-30 Barry M. Tydings Assaying device and method for in field urinalysis
WO2001073057A1 (en) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 19053, a novel atpase-like molecule and uses thereof
CN1315402A (zh) * 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
CN1323833A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白51和编码这种多肽的多核苷酸
ATE554169T1 (de) 2001-11-02 2012-05-15 Giuliani Int Ltd Smad7-inhibitoren zur behandlung von krankheiten des zns
US6805838B2 (en) 2002-03-04 2004-10-19 Barry M. Tydings Assaying device and method for in field urinalysis
NZ536054A (en) * 2002-04-09 2009-10-30 Scripps Research Inst Motif-grafted hybrid polypeptides and uses thereof
US7771952B2 (en) 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
EP2053409A1 (de) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Spezifische Marker für Stoffwechselsyndrome
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011083147A1 (en) 2010-01-08 2011-07-14 Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
US20130116304A1 (en) 2010-04-19 2013-05-09 Ernst R. Werner Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
MY176695A (en) 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US20220133808A1 (en) * 2019-02-01 2022-05-05 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702789A1 (de) * 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0002911A2 *

Also Published As

Publication number Publication date
AU4869399A (en) 2000-02-01
JP2002521004A (ja) 2002-07-16
WO2000002911A3 (en) 2001-01-18
WO2000002911A2 (en) 2000-01-20
CA2332625A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
US6627405B1 (en) 53BP2 complexes
EP1095154A2 (de) Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon)
US20030064477A1 (en) Novel E6 targeted protein (E6TP1)
JP2002510490A (ja) Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
US6476193B1 (en) NLK1 protein and NLK1 protein complexes
US6521412B1 (en) HsReq*1 and hsReq*2proteins and use thereof to detect CDK2
AU770000B2 (en) Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof
JP4249927B2 (ja) コラーゲン様新規蛋白ｃｌａｃおよびその前駆体、ならびにそれらをコードする遺伝子
WO2001068846A2 (en) Transcription activator of the cited family
AU4690499A (en) Interaction of p27(kip1) with fkbp-12
KR100811926B1 (ko) 파킨 유전자 활성의 조절에 유용한 조성물
CA2319782A1 (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins
JP4709383B2 (ja) Ｕｃｐ４
JPWO2002064770A1 (ja) 新規スカベンジャー受容体クラスａ蛋白質
US7342102B2 (en) Uncoupling protein 5 (UCP5)
US6967245B2 (en) Ucp5
JP2002533062A5 (de)
AU3291799A (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030903

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040316